Skip to contentC
Calidi Biotherapeutics, Inc.
C
CLDICalidi Biotherapeutics, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$4.06M-$4.06MderivedN/M vs Q4 2024 EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$4,466,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Calidi Biotherapeutics, Inc. · CIK 1855485 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,044,000N/M ended Dec 31, 2025 · filed Mar 27, 2026 · 86 d after period end